Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) major shareholder Foresite Capital Management V, purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Latigo Biotherapeutics Stock Performance
NASDAQ:LTGO traded up $0.31 on Monday, hitting $18.56. The company’s stock had a trading volume of 598,445 shares. Latigo Biotherapeutics, Inc. has a one year low of $17.22 and a one year high of $22.47.
Featured Articles
- Five stocks we like better than Latigo Biotherapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
